Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for treating eosinophilic granulomatosis with polyangiitis has experienced robust expansion recently, projected to increase from $1.41 billion in 2025 to $1.54 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.8%. This historical growth trajectory has been fueled by rising awareness of autoimmune conditions, a continued reliance on corticosteroids for management, enhanced capabilities in diagnosing rare diseases, advancements in hospital-based immunology services, and the persistent need for effective inflammation control.

The market for eosinophilic granulomatosis with polyangiitis treatments is projected for substantial expansion in the upcoming years, reaching an estimated $2.22 billion by 2030 with a compound annual growth rate of 9.6%. This anticipated growth trajectory is fueled by advancements in biologic drug development, increased financial backing for rare diseases, the emergence of tailored autoimmune therapies, the proliferation of specialized clinics, and the implementation of proactive intervention strategies. Key developments expected during this forecast period encompass a greater adoption of targeted biologic treatments, a heightened emphasis on addressing rare autoimmune conditions, a rise in long-term immunosuppressive therapies, the expansion of specialized autoimmune healthcare services, and a growing focus on achieving early control of the disease.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23392&type=smp

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?

The increasing prevalence of allergic reactions is anticipated to be a significant catalyst for the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market. A contributing factor to the surge in these reactions is escalating air pollution, where airborne irritants like smoke, dust, and chemicals can overstimulate the immune system, heightening sensitivity to allergens. Consequently, as allergic responses become more widespread, there is a corresponding rise in individuals developing conditions associated with an overactive immune system, including EGPA, which in turn elevates the need for therapies that can manage inflammation and associated symptoms. Highlighting this trend, in 2024, PubMed, affiliated with the US National Institutes of Health, reported that among individuals with food allergies, the most frequently observed allergic comorbidities included atopic dermatitis at 48%, asthma at 46%, and allergic rhinitis at 39%. Moreover, a substantial proportion of patients, 42%, reported experiencing multiple food-related allergic reactions annually, with 46% suffering from food-induced anaphylaxis. Hence, the heightened incidence of allergic reactions is directly contributing to the growth trajectory of the EGPA treatment market.

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Segment Performance And Strategic Opportunities

The eosinophilic granulomatosis with polyangiitis treatment market covered in this report is segmented –

1) By Drug Class: Steroids, Immunosuppressant, Biologics, Immune Globulins

2) By Route Of Administration: Oral, Intravenous, Intramuscular

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Drug Stores, Retail Pharmacies

4) By End User: Hospitals, Clinics, Home Healthcare

Subsegments:

1) By Steroids: Glucocorticoids, Mineralocorticoids

2) By Immunosuppressants: Calcineurin Inhibitors, Antimetabolites, Alkylating Agents

3) By Biologics: Interleukin Inhibitors, Monoclonal Antibodies, TNF-alpha Inhibitors

4) By Immune Globulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Trends: What Is Shaping Future Industry Growth?

Key players in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment arena are actively engaged in clinical investigations to evaluate the therapeutic profiles of both novel and established treatments. These studies are instrumental in broadening treatment choices, obtaining necessary regulatory endorsements, and ultimately elevating the standard of patient management. As an illustration, in September 2024, AstraZeneca, a prominent pharmaceutical and biotechnology firm headquartered in the United Kingdom, shared favorable outcomes from the MANDARA Phase III study. This trial provided evidence that Fasenra (benralizumab) demonstrates efficacy in achieving remission among individuals diagnosed with eosinophilic granulomatosis with polyangiitis. The data indicated that benralizumab yielded remission rates on par with mepolizumab, concurrently diminishing the reliance on oral glucocorticoids. Such progress marks a crucial stride towards more focused treatment strategies for EGPA that minimize steroid usage.

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma

Access The Complete Eosinophilic Granulomatosis With Polyangiitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/eosinophilic-granulomatosis-with-polyangiitis-treatment-global-market-report

Eosinophilic Granulomatosis With Polyangiitis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model